克劳丁18.2作为一种新的治疗点
Izuma Nakayama1, Changsong Qi2, Yang Chen2
1Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Nature reviews. Clinical oncology
|March 20, 2024
概括
克劳丁18.2是晚期胃癌的一个有希望的目标. 针对这种分子的疗法,如佐尔贝图西马布,为克劳丁18.2阳性瘤患者提供了新的治疗选择.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫治疗是一种免疫疗法.
背景情况:
- 克劳丁18.2是一种紧结蛋白,在正常的胃上皮表达,但在恶性细胞上变得可访问.
- 这种可访问性使得克劳丁18.2成为新型癌症治疗的有吸引力的标.
研究的目的:
- 审查在晚期胃癌中针对克劳丁18.2的治疗方法的生物学理由和临床活性.
- 探索克劳丁18.2向疗法的潜在扩展到其他固体瘤.
主要方法:
- 复查了对抗克劳丁18.2抗体索尔贝图西马布III期试验的数据.
- 分析新兴疗法,包括单克隆抗体,双特异性抗体,CAR T细胞和抗体与药物合物.
主要成果:
- 索尔贝图西马布加化疗确立了克劳丁18.2阳性晚期胃癌作为一个独特的治疗子集.
- 新的向疗法对表达克劳丁18.2的胃癌有前途,扩大了传统向之外的治疗选择.
结论:
- 向克劳丁18.2显著增加了患者在晚期胃癌中接受向治疗的资格.
- 克劳丁18.2向疗法代表着一个范式的转变,在其他克劳丁18.2阳性固体瘤中具有潜在的应用.
更多相关视频
06:43Functional Assessment of Intestinal Tight Junction Barrier and Ion Permeability in Native Tissue by Ussing Chamber Technique
Published on: May 26, 2021
5.5K
06:59A Fluorescence-Based Assay of Membrane Potential for High-Throughput Functional Study of Two Endogenous Ion Channels in Two Epithelial Cell Lines
Published on: June 22, 2022
2.1K
相关概念视频
Tight Junctions
5.3K
Tight junctions are molecular seals between cells that prevent the leaking of fluids, ions, and other small solutes across cavities and compartments in multicellular organisms. They are mainly composed of claudin and occludin transmembrane proteins, and other proteins such as tricellulin and JAM (junctional adhesion molecule). All these proteins are 4-pass transmembrane proteins, except JAM, which is a single-pass transmembrane protein belonging to the immunoglobulin superfamily. The...
5.3K
Clathrin Coated Vesicles
7.0K
Clathrin-coated vesicles use endocytosis to transport receptors and lysosomal hydrolases from the Golgi to the lysosome in the late secretory pathway. Clathrin-mediated endocytosis was the first described endocytic process, and Clathrin-coated vesicles remain one of the most well-studied transport vesicles. The molecular machinery that generates clathrin-coated vesicles comprises over 50 proteins that precisely coordinate vesicle formation. Cell surface receptors concentrated in indented sites...
7.0K
Pinching-off of Coated Vesicles
3.1K
Vesicle budding is orchestrated by distinct cytosolic proteins such as adaptor proteins, coat proteins, and GTPases. To initiate vesicle budding, membrane-bending proteins containing crescent-shaped BAR domains bind to the lipid heads in the bilayer and distort the membrane to form a protein-coated vesicle bud. Adaptors proteins such as AP2 for clathrin-coated vesicles can nucleate on the deformed membrane. Finally, coat proteins such as clathrin or COPI and COPII assemble into a coat forming...
3.1K
Adherens Junctions
4.8K
Strong contact points between adjacent cells anchor them to each other, forming tissues. Such anchoring junctions are of two types – adherens junctions and desmosomes. Adherens junctions are abundant in tissues such as epithelium and endothelium, forming a continuous zone of adhesion called the adhesion belt. In other tissues, such as heart muscle, they appear as clusters, linking the cells to produce coordinated heart muscle contraction.
Adherens Junctions are Dynamic
Adherens Junctions are Dynamic
4.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
